Two Penguins Investment
Preparing your financial briefing…
Financial Intelligence
Recent perspective
Recent financial reporting selected by recency, stored importance, and source diversity.
Live chronology
Page 529 · Newest reporting first
Nasdaq Marketscentral bankspolicy decision
Fed Chair Kevin Warsh signaled a shift in the central bank's focus on inflation. The article highlights a reform-oriented approach to monetary policy.
Nasdaq Marketsmarketsinvestment opinion
Kraken Robotics stock has pulled back sharply after reaching a lifetime high in March 2026. The article discusses whether September presents a buying opportunity.
Nasdaq Marketscompaniescorporate event
Anthropic may reportedly choose not to lock up a portion of insider shares when it launches its IPO. The article examines the potential implications of longer lockup periods.
Nasdaq Marketscompaniesmarket event
Rocket Lab shares are under pressure amid reports that the Neutron rocket may be delayed to 2027. The decline comes even as the company's revenue continues to grow strongly.
Nasdaq Marketscompaniesroutine announcement
Ameren SVP of Finance Ryan Martin sold 971 shares in a transaction valued at approximately $107,000. The filing discloses an insider stock sale by a senior executive.
Nasdaq Marketsmarketsinvestment opinion
The article presents a personal investment case for continuing to hold VTI regardless of market conditions. It cites long-term S&P 500 returns, including a 593% total return since September 2011.
Nasdaq Marketsmarketsinvestment opinion
The article discusses how stock markets fluctuate over time while maintaining a long-term upward trend. It suggests that historical market data can guide investor responses to a potential downturn.
CNBC Top Newsotherroutine announcement
A Japanese nutritionist shares seven anti-inflammatory foods she keeps in her kitchen, with no direct financial or market relevance.
Nasdaq Marketsmarketsinvestment opinion
The article calculates that an investor would need 3,456 shares of Procter & Gamble to collect $15,000 in annual dividends. It focuses on the share count required to reach a specific dividend income target.
Nasdaq Marketscompaniesinvestment opinion
Gilead Sciences received its third FDA approval in less than four months. The article questions whether the stock still underrates the company's turnaround potential.